DreamPharm Products:
Gan To Kagaku Ryoho 2003 Jan;30(1):105-9
Weekly administration of paclitaxel and pirarubicine for recurrent breast cancer
The therapeutic efficacy of weekly coadministration of paclitaxel (TXL) and pirarubicin (THP) on docetaxel (TXT)- and epirubicin-resistant recurrent breast cancer, adverse reactions caused by this therapy, and the possibility of ambulatory treatment using it were evaluated. The present study was conducted in 11 patients with recurrent breast cancer with pretreatment with CEF and TXT. The site of recurrence was the lung in 9 patients, lymphnodes in 2, bones in 1, liver in 1 and local foci in 1. One cycle consisted of 20 mg/m2 of THP followed by 80 mg/m2 of TXL 4 h later, repeated three times every other week. Three to six cycles were conducted in each patient. An anti-emetic drug was administered before administration of THP as short premedication. Dexamethasone (16 mg; i.v.) and d-chlorpheniramine maleate (12 mg; p.o.) were administered 1 h before administration of TXL and ranitidine (100 mg; i.v.) was administered 30 min before administration of TXL. Ubidecarenone (30 mg/day; p.o.) was administered for 3 days. The response rate was 27.3% with a rating of PR in 3 patients, NC in 6, and PD in 2. Adverse reactions observed included transient facial hot flushes, alopecia grade 1 or milder grade 1 symptoms, and peripheral nerve damage. No adverse reactions such as myocardial disorders or congestive heart failure were noted. Grade 3 and grade 2 neutropenia occurred in 1 and 6 patients, respectively, and 4 patients were admitted for treatment of this. In conclusion, the short premedication was useful, and this was thought to make it possible to conduct ambulatory treatment with TXL + THP in some patients. The response rate of 27.3%, however, was not satisfactory. It will be necessary to clarify the characteristics of this therapy by administering it to a wider spectrum of patients.
Kaohsiung J Med Sci 2002 Aug;18(8):379-85
Finasteride in the treatment of Taiwanese men with androgenetic alopecia: a 12-month open-label study.
Finasteride 1 mg/day is effective in the treatment of androgenetic alopecia (AGA). Our open-label study assessed the efficacy and safety of finasteride for the treatment of Taiwanese men with AGA. We enrolled 34 Taiwanese men (aged 18-40 yr) with AGA of modified Norwood/Hamilton scale (MNHS) grade II-V. In investigator assessments at 12 months, five of 21 subjects (23.8%) had two-grade improvement in MNHS grade and 12 of 21 subjects (57.1%) had one-grade improvement; the others remained at the same grade. In global photographic evaluation, five of 31 subjects (15.1%) had observable hair growth at 6 months and 11 of 21 subjects (52.4%) had observable hair growth at 12 months. Patient self-assessment of hair growth was favorable across all questions in the treatment course, more significantly at 12 months than at 6 months; nine of 21 subjects (42.9%) were satisfied with their overall appearance at 12 months. Serum prostate specific antigen levels had decreased by 23.4% at 12 months. Adverse effects, including abnormal liver function (5/34), were minimal, and the causal relationship with finasteride could not be established. Thus, in Taiwanese men with AGA, finasteride 1 mg/day for 1 year slowed the progression of hair loss and increased hair growth.
J Am Acad Dermatol 2002 Apr;46(4):541-4
Sulfasalazine for alopecia areata.
Sulfasalazine is used as a therapy for various autoimmune conditions, including psoriasis; its effectiveness is presumed to be the result of its immunomodulatory effects. We have treated patients with severe alopecia areata with sulfasalazine as part of our dermatology practice and have noticed cosmetically acceptable regrowth in 23% of patients in whom a response could be determined. In view of its good safety profile, sulfasalazine may be considered for systemic treatment of severe alopecia areata.
Gan To Kagaku Ryoho. 2003 May;30(5):653-9.
Weekly paclitaxel administration in the adjuvant therapy of primary breast cancer
PURPOSE: To investigate feasibility and toxicity of weekly paclitaxel administration in the adjuvant therapy of primary breast cancer. PATIENTS AND METHODS: Thirty-one patients with primary breast cancer received sustained weekly infusion of paclitaxel at a dose of 90 mg/body for 6 weeks followed by a 2-week interval. This weekly schedule was repeated twice. Leukocytes were checked immediately before every infusion and the dose was reduced to 80 mg/body when grade 1 neutropenia occurred. All patients were assessable for feasibility and toxicity. RESULTS: A total 349 weekly paclitaxel infusions were administrated to 31 patients (median, 12 infusions/patient). The median delivered dose-intensity was 88.0 mg/body/week (range 80 to 90). Therapy was well tolerated and completed in 27 patients. Four patients refused to continue the therapy because of nausea, fatigue, dizziness and weight gain. Grade 2 neutropenia occurred in 10 patients (32.3%), but grade 3 neutropenia did not occur. Grade 1 peripheral neuropathy occurred in 3 patients (9.7%). Grade 1 nausea occurred in 3 patients (9.7%). CONCLUSION: Weekly paclitaxel administration is well tolerated with a favorable toxicity profile in patients with primary breast cancer in the adjuvant setting. Weekly paclitaxel therapy can be performed safely in the outpatient setting.
Made of well known Chinese traditional herbs, Hair Million is a herbal hair restoration formula that addresses hair loss problems.
Since the herbs have been in use for thousands of years, there have been numerous anecdotal cases so far that Hair Million herbs can really improves the age-related hair thinning and hair loss for a significant fraction of people who take it diligently.
It is unknown how Hair Million stops hair loss, and promotes hair growth, despite all the anecdotal observations.
Neither scientific research nor placebo controlled clinical trials has been conducted due to the cost.
Shortage or total lack of scientific/clinical research is not uncommon in herbal/nutritional arena.
It is not reasonable to stop taking daily food and herbal supplements altogether just because of scietific/clinical support: our life must go on while we stive to better understand food and herb.
There are two merits that Hair Million enjoys: Firstly, Hair Million is relatively inexpensive, and secondly, it is made only of edible herbs that are known to be safe when consumed in regular quantities. Propecia is a clinically tested prescription drug for hair loss treatment.
DHEA has been suggested to provide numerous potential benefits. DHEA (or dehydroepiandrosterone) is converted into androgens (male hormones)
or estrogens (female hormones) in the cells.
Our bodies produce decreasing amount of DHEA as we get older.
various health benefits: To deter aging,
improve sexual function/erectile dysfunction, treat cognitive decline, enhance athletic performance,
facilitate weight loss, improve strength, prevent osteoporosis, enhance immunomodulation for rheumatic conditions,
and treat depression.
Herbs and Pharmaceuticals Online||
Constipation relief, laxative, colon cleansing ||
Best Realtor in Glendale, California: Residential Home and Commercial Property ||
Related Web pages ||
Herbs and Pharmaceuticals Online ||